AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) traded up 8.9% during mid-day trading on Wednesday after HC Wainwright raised their price target on the stock from $38.00 to $59.00. Wedbush reiterated an “outperform” rating and issued a $45.00 price target on shares of AnaptysBio in a report on Tuesday. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $48.75. The biotechnology company reported ($1.34) EPS for the quarter, beating the consensus estimate of ($1.50) by $0.16. About AnaptysBio(Get Free Report)AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics.